Bill Text: CA SB746 | 2019-2020 | Regular Session | Amended
Bill Title: Health care coverage: anticancer medical devices.
Spectrum: Partisan Bill (Republican 2-0)
Status: (Engrossed - Dead) 2019-08-30 - August 30 hearing: Held in committee and under submission. [SB746 Detail]
Download: California-2019-SB746-Amended.html
|
Amended
IN
Assembly
May 30, 2019 |
CALIFORNIA LEGISLATURE—
2019–2020 REGULAR SESSION
| Senate Bill | No. 746 |
| Introduced by Senator Bates (Coauthor: Senator Wilk) |
February 22, 2019 |
An act to add Section 1367.667 to the Health and Safety Code, and to add Section 10123.837 to the Insurance Code, relating to health care coverage.
LEGISLATIVE COUNSEL'S DIGEST
SB 746, as amended, Bates.
Health care coverage: anticancer medical devices.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law requires health care service plan contracts and health insurance policies to cover certain medical services for particular types of cancer, including the screening, diagnosis, and treatment of breast cancer, and the screening and diagnosis of prostate cancer, if the contract or policy was issued, amended, or renewed after the applicable date.
This bill would require health care service plan contracts and health insurance policies issued, amended, or renewed on or after January 1, 2020, that cover chemotherapy or radiation therapy for the treatment of cancer to also cover anticancer medical devices. The
bill would define “anticancer medical device” as a medical device that has been approved for marketing by the federal Food and Drug Administration or is exempt from that approval, is primarily designed to be used outside of a medical facility, and has been prescribed by an authorized provider upon the provider’s determination that the device is medically reasonable and necessary for the treatment of the patient’s cancer. Because a violation of this bill’s provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YESBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 1367.667 is added to the Health and Safety Code, immediately following Section 1367.665, to read:1367.667.
(a) Every health care service plan contract issued, amended, or renewed in this state on or after January 1, 2020, that provides coverage for chemotherapy or radiation therapy for the treatment of(b) For purposes of this section, “anticancer medical device” means a medical device, including component parts, services, and supplies necessary for the effective use of the device, that meets all of the following criteria:
(1) The device has been cleared or approved for marketing by the federal Food and Drug Administration, if that clearance or approval is required by law.
(2) The device is primarily and substantially designed for use outside of a medical treatment facility, or use for which reimbursement is not ordinarily provided as incident to a provider’s professional service or as part of a provider’s fee for service.
(3) The device is prescribed by a provider authorized to prescribe that device for the treatment of cancer, upon a determination by the provider that the device is medically reasonable and necessary for the treatment of the patient.
SEC. 2.
Section 10123.837 is added to the Insurance Code, immediately following Section 10123.835, to read:10123.837.
(a) Every policy of(b) For purposes of this section, “anticancer medical device” means a medical device, including component parts, services, and supplies necessary for the effective use of the device, that meets all of the following criteria:
(1) The device has been cleared or approved for marketing by the federal Food and Drug Administration, if that clearance or approval is required by law.
(2) The device is primarily and substantially designed for use outside of a medical treatment facility, or use for which reimbursement is not ordinarily provided as incident to a provider’s professional service or as part of a provider’s fee for service.
(3) The device is prescribed by a provider
authorized to prescribe that device for the treatment of cancer, upon a determination by the provider that the device is medically reasonable and necessary for the treatment of the patient.
